Shareholders Approve Response Biomedical's C$8M Private Placement | GenomeWeb

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Response Biomedical today announced shareholders have approved the private placement of an aggregate of more than 13.3 million shares to Caduceus Private Investments III, OrbiMed Associates III, and Caduceus Asia Partners.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.